Back to Top

Monthly Webinar

October 14, 2021: Dr. Susan Weiss, Cannabis Research and Policy: State of the Science

Dr. Susan Weiss is the Director, Division of Extramural Research at the National Institute on Drug Abuse (NIDA), which oversees NIDA’s extramural programs, operations planning, and trans-NIH initiatives, such as the Adolescent Brain Cognitive Development (ABCD®) and HEALthy Brain Child Development (HBCD) studies, and the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative. Dr. Weiss also serves as a senior science advisor to the NIDA Director and scientific liaison to the NIH, HHS, and other Federal Agencies. Previously, she served as the Chief of the Science Policy Branch and Acting Director of NIDA's Office of Science Policy and Communications.

Before coming to NIDA, Dr. Weiss was the Senior Director of Research at the National Mental Health Association (now Mental Health America), and previously she directed a translational research program in the Biological Psychiatry Branch of the National Institute of Mental Health.

Dr. Weiss received multiple awards, including NIH Plain Language Awards, NIH and NIDA Director’s Awards, and an Emmy for her contributions to the HBO Addiction Project. She has published more than 150 scientific articles and chapters, graduated from the State University of New York at Stony Brook, and received her Ph.D. in Psychology from the University of Maryland. 

 

Previous Webinars Videos

  •  

    September 9, 2021: Dr. Gillian Schauer: Delta-8 THC and other THC Analogs: Public Health and Safety Considerations

    Gillian Schauer, PhD, MPH, is the Executive Director of the Cannabis Regulators Association (CANNRA) and a Senior Consultant on cannabis policy, epidemiology, and research translation. Her consulting has included work with the U.S. Centers for Disease Control and Prevention, the National Institute on Drug Abuse, and a number of U.S. states. Dr. Schauer is also affiliated as a Research Scientist at the Addictions, Drug & Alcohol Institute at the University of Washington. Prior to her work in cannabis policy, Dr. Schauer worked in tobacco prevention and control. She has more than 65 peer-reviewed publications on cannabis, tobacco, and co-use, and was a Senior Editor on the 2020 Surgeon General’s Report on Smoking Cessation. She has a PhD from Emory University in Behavioral Science, a Master of Public Health from the University of Washington, and a Bachelors of Science from Northwestern University.

    View the September webinar

  •  

    July 2021 - Dr. Ziva Cooper, Looking Beyond Delta-9-THC

    Ziva Cooper
    Title: Human Studies Probing Cannabis Constituents For Pain Relief: Looking Beyond Delta-9-THC

    Dr. Ziva Cooper is the Director of the UCLA Cannabis Research Initiative in the Jane and Terry Semel Institute for Neuroscience and Human Behavior and Associate Professor in the Department of Psychiatry and Biobehavioral Sciences and Department of Anesthesiology at the David Geffen School of Medicine. Her current research involves understanding variables that influence both the therapeutic potential and adverse effects of cannabis and cannabinoids through double-blind, placebo-controlled studies.

    Current funded projects include 1) understanding differences between men and women in their response to the abuse-related and pain-relieving effects, and the role that circulating hormones and endocannabinoids contribute to these differences, 2) the potential for THC and CBD to reduce reliance on opioids, 3) impact of cannabis use on HIV-associated inflammation, and 4) the effectiveness of cannabidiol to address symptoms associated with rheumatoid arthritis.

    Dr. Cooper served on the National Academies of Sciences Committee on the Health Effects of Cannabis that recently published a comprehensive consensus report of the health effects of cannabis and cannabinoids. She is past president of the International Study Group Investigating Drugs as Reinforcers, a Board Director for the College on Problems of Drug Dependence, an Associate Editor of The American Journal of Drug and Alcohol Abuse, and is on several Editorial Boards of journals including Cannabis and Cannabinoid Research and Neuropsychopharmacology.

    View July 2021 Webinar Video

  •  

    June 2021 - Dr Clayton W Snell, A Deep Dive into Epidiolex

    Clayton W Snell
    Title: A Deep Dive into Epidiolex

    Clayton W. Snell, PharmD, received his degree from the University of the Sciences in Philadelphia and started working in neurology right after graduation. He completed a fellowship with Rutgers University and Acorda Therapeutics, where he focused on multiple sclerosis and Parkinson’s disease. He has worked in a number of other therapeutic areas including epilepsy, ADHD, migraine, and spinal cord injury. He joined Greenwich Biosciences in 2020, allowing him to continue his work in epilepsy and develop cannabis-based FDA-approved products. Currently located in Denver, CO, Clayton enjoys hiking the state and national parks as well as hanging out with his cat, Gumbo.

    View June 2021 Webinar Video

  •  

    May 2021 - Ajay Nayak & George Hodgin, Academic and Business Perspectives of Compliance in Cannabis Research

    George Hodgin
    Title: Access to Federally Compliant Cannabis for Research
    George Hodgin is the Founder and CEO of Biopharmaceutical Research Company (BRC), an applicant with the Drug Enforcement Administration to produce federally compliant cannabis products for research. BRC holds several DEA Schedule I Registrations and engages in compliant cannabis research. He is a former Navy SEAL officer and alumnus of the Stanford University Graduate School of Business. He was commissioned as an officer in the Navy in 2009, after earning a BA in Economics and Mandarin from the University of North Carolina at Chapel Hill, where he was a Morehead-Cain scholar. George led SEALs in combat in counter-terrorism operations in Afghanistan and Southeast Asia. His hobbies include fly-fishing and hiking with his family and dog. He and his wife and two sons live in Carmel-By-the-Sea, California.

    Ajay Nayak
    Title: Navigating through cannabis research: an academic story of partnerships and collaborations
    Ajay Nayak is an Assistant Professor in the Department of Medicine at Thomas Jefferson University, Philadelphia. He has an appointment in the Center for Translational Medicine and the Division of Pulmonary, Allergy and Critical Care Medicine at TJU. Ajay received his B.Sc. and M. Sc. In Microbiology from the University of Mumbai and came to the US in 2006 to pursue his doctoral degree from West Virginia University. Ajay was a civilian employee with the Federal government at CDC/NIOSH in Morgantown, WV. Ajay has been actively involved in cannabis research efforts for almost a decade. His primary areas of interest in the field of allergy. He is also interested in examining the physiological and pathophysiological effects of cannabis on human health. He is engaged in multiple collaborations both nationally and internationally to further cannabis research. His lab has an active research grant from NIH to develop diagnostic tools for determining cannabis allergies.

    View May 2021 Webinar Video

  •  

    April 2021 - Dr. Cristina Sempio, Cannabinoids and Endocannabinoids in Human Breast Milk

    Cannabinoids and Endocannabinoids in Human Breast Milk

    The Institute of Cannabis Research’s monthly webinar for April 2021 featured Dr. Cristina Sempio. Dr. Sempio is a Research Instructor in the Department of Anesthesiology at the University of Colorado Anschutz Medical Campus. She earned her PhD in forensic sciences at the University of Verona (Italy), developing cutting-edge analytical methods for the screening and quantification of drugs of abuse in different biological matrices. After an internship at the National Institute on Drug Abuse under the supervision of Dr. Huestis, she joined the University of Colorado Anschutz Medical Campus as a postdoctoral fellow. Dr. Sempio is currently collaborating on several CDPHE and NIH grants to elucidate the therapeutic potential of cannabinoids and their influence on the endocannabinoids system. Dr. Sempio supervises and manages the iC42 Clinical Research and Development’s clinical toxicology laboratory and is responsible for all industry collaborations and analytics for cannabis and hemp-based drug developments. Other projects ongoing in her laboratory investigate the effect of cannabinoids administration on endocannabinoids and lipid mediators. The registration link will be listed once it's ready.

    View April 2021 Webinar Video

  •  

    Mar 2021 - Dr. Sara Jane Ward , Phytocannabinoids, Terpenes, and Neuropathic Pain

    The Institute of Cannabis Research’s monthly webinar for March 2021 featured Dr. Sara Jane Ward. She is the Assistant Professor from Temple University. Her research focuses on the behavioral pharmacological effects of the cannabinoid, serotonin, and opioid receptor systems on neuropathic pain and neuroprotection, learning and memory, and addiction. Her research makes use of rodent models of peripheral and central nerve injury, substance abuse, and cognition to explore the pharmacotherapeutic potential of cannabinoid, serotonergic, and opiodergic compounds alone and in combination on these behavioral endpoints. She presented a webinar titled "Phytocannabinoids, Terpenes, and Neuropathic Pain".

    View March 2021 Webinar Video

  •  

    February 2021 - Dr. Ashley Brooks-Russell, Cannabis Impaired Driving and Questions About Tolerance

    The Institute of Cannabis Research’s monthly webinar for February 2021 featured Dr. Ashley Brooks-Russell from The University of Colorado Anschutz Medical Campus. Dr. Brooks-Russell is an assistant professor and Director of the Program for Injury Prevention, Education and Research Program at the Colorado School of Public Health, CU Anschutz. She completed her Ph.D. in Health Behavior at the University of North Carolina at Chapel Hill and a postdoctoral fellowship at the National Institute of Child Health and Human Development (NIH). Her recent work has focused on cannabis use and the association of policy changes with changes in cannabis use and related outcomes. She presented a webinar titled "Cannabis Impaired Driving and Questions About Tolerance".

    View February 2021 Webinar Video

  •  

    December 2020 - Dr. Mahmoud A. ElSohly, Cannabis Derived Products from the University of Mississippi

    Cannabis Derived Products from the University of Mississippi

    Dr. ElSohly serves as Research Professor in the National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, and Professor of Pharmaceutics in the School of Pharmacy at the University of Mississippi. Dr. ElSohly is the director of the Marijuana Project at the University of Mississippi, which is funded by the National Institute on Drug Abuse.​

    Dr. ElSohly holds more than 30 patents dealing with the processing, testing, and detection of drugs of abuse along with those dealing with biologically active natural products. He has authored over 250 scholarly articles and more than 200 presentations at scientific meetings of professional societies relative to drug discovery, analysis, and metabolism, and many of his articles deal with forensic issues of drugs of abuse. He was recognized by The Scientist (April 17, 1995), Science Watch (January 1995), and the Journal of Analytical Toxicology (October issue, 2004) for his accomplishments.​

    View December 2020 Webinar Video

  •  

    November 2020 - Dr. David Shurtleff, Cannabinoid Research Funding Opportunities at NCCIH

    Cannabinoid Research Funding Opportunities at NCCIH

    David Shurtleff, Ph.D., is Deputy Director of the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH), the leading Federal agency for research on integrative and complementary health practices. Dr. Shurtleff’s career at the NIH has focused on providing leadership and fostering an extensive research portfolio in the basic behavioral and neurosciences—cognitive studies, behavioral economics, decision theory, and risk-taking—and a broad spectrum of research that has contributed to cutting-edge research related to drug abuse, addiction, and their treatment. 

    View November 2020 Webinar Video

  •  

    October 2020 - Dr. Stephanie McGrath, Cannabis Use in Pets

    Cannabis Use in Pets - Clinical Trials at Colorado State University

    The inaugural webinar featured Dr. Stephanie McGrath, Associate Professor, Neurology/Neurosurgery in College of Veterinary Medicine and Biomedical Science at Colorado State University in Fort Collins.

    Dr. McGrath addressed her groundbreaking studies in the use of cannabidiol (CBD) for dogs with epilepsy, as well as her recent work with how canine glioma cells respond to CBD.

    View October 2020 Webinar Video

Spring 2022 Registration

Registration Opens October 18, 2021.

To register for Spring 2022 courses, students will need to meet with their academic success coach or faculty mentor, submit proof of vaccination or exemption, and self-register through Banner.

Vaccination Requirement and Exemptions

Student wearing face mask

The university's COVID-19 Vaccination Policy includes the COVID-19 vaccination unless an exemption is filed.

Join our Distribution List!

Institute of Cannabis Research

Faculty and Staff

Back to Top